Literature DB >> 10411546

Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.

M V Dhodapkar1, R M Steinman, M Sapp, H Desai, C Fossella, J Krasovsky, S M Donahoe, P R Dunbar, V Cerundolo, D F Nixon, N Bhardwaj.   

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells that initiate protective T-cell immunity in mice. To study the immunogenicity of DCs in humans, we injected 9 healthy subjects subcutaneously with a control injection of autologous monocyte-derived, mature DCs, followed 4-6 weeks later by DCs pulsed with keyhole limpet hemocyanin (KLH), HLA-A*0201-positive restricted influenza matrix peptide (MP), and tetanus toxoid (TT). Four more subjects received these antigens without DCs. Injection of unpulsed DCs, or antigens alone, failed to immunize. Priming of CD4(+) T cells to KLH was observed in all 9 subjects injected with KLH-pulsed DCs, and boosting of TT-specific T-cell immunity was seen in 5 of 6 subjects injected with TT-pulsed DCs. Injection of antigen-pulsed DCs led to a severalfold increase in freshly isolated MP-specific, IFN-gamma-secreting CD8(+) T cells in all 6 HLA-A*0201-positive subjects, as early as 7 days after injection. When T cells were boosted in culture, there was an increase in MHC tetramer-binding cells and cytotoxic T cells after DC vaccination. These data provide the first controlled evidence of the immunogenicity of DCs in humans, and demonstrate that a single injection of mature DCs rapidly expands T-cell immunity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411546      PMCID: PMC408478          DOI: 10.1172/JCI6909

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells.

Authors:  A Reddy; M Sapp; M Feldman; M Subklewe; N Bhardwaj
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

2.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

Review 3.  Antiviral immunity.

Authors:  R M Zinkernagel; H Hengartner
Journal:  Immunol Today       Date:  1997-06

4.  Induction of antitumor immunity using bone marrow-generated dendritic cells.

Authors:  A Porgador; D Snyder; E Gilboa
Journal:  J Immunol       Date:  1996-04-15       Impact factor: 5.422

5.  Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells.

Authors:  N Bhardwaj; A Bender; N Gonzalez; L K Bui; M C Garrett; R M Steinman
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 6.  Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines.

Authors:  J I Mayordomo; T Zorina; W J Storkus; L Zitvogel; M D Garcia-Prats; A B DeLeo; M T Lotze
Journal:  Stem Cells       Date:  1997       Impact factor: 6.277

Review 7.  Dendritic cells as adjuvants for immune-mediated resistance to tumors.

Authors:  G Schuler; R M Steinman
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

8.  Rapid effector function in CD8+ memory T cells.

Authors:  A Lalvani; R Brookes; S Hambleton; W J Britton; A V Hill; A J McMichael
Journal:  J Exp Med       Date:  1997-09-15       Impact factor: 14.307

9.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Authors:  L Zitvogel; J I Mayordomo; T Tjandrawan; A B DeLeo; M R Clarke; M T Lotze; W J Storkus
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

10.  Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.

Authors:  C M Celluzzi; J I Mayordomo; W J Storkus; M T Lotze; L D Falo
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  102 in total

1.  Dendritic cells: at the clinical crossroads.

Authors:  J J Mulé
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

2.  HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other.

Authors:  P J Goulder; Y Tang; S I Pelton; B D Walker
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 3.  Active immunization of humans with dendritic cells.

Authors:  M V Dhodapkar; N Bhardwaj
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

Review 4.  Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance.

Authors:  Ralph Marvin Steinman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

Review 5.  Development and use of multimeric major histocompatibility complex molecules.

Authors:  Tim F Greten; Jonathan P Schneck
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

6.  Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis.

Authors:  Y Morita; J Yang; R Gupta; K Shimizu; E A Shelden; J Endres; J J Mulé; K T McDonagh; D A Fox
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

7.  Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection.

Authors:  Gareth D Healey; Stephen J Elvin; Margaret Morton; E Diane Williamson
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

8.  Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.

Authors:  Douglas G McNeel; Keith L Knutson; Kathy Schiffman; Donna R Davis; Dania Caron; Mary L Disis
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

9.  An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.

Authors:  Xinmei Zhu; Chuanzhen Lu; Baoguo Xiao; Jian Qiao; Yi Sun
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

10.  Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production.

Authors:  Sandesh Subramanya; Sang-Soo Kim; Sojan Abraham; Jiahong Yao; Mukesh Kumar; Priti Kumar; Viraga Haridas; Sang-Kyung Lee; Leonard D Shultz; Dale Greiner; Manjunath N; Premlata Shankar
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.